CBD Cosmetics in the US: When a Skin Cream Becomes a Drug

Rules checked: November 9, 2026. Laws and agency guidance can change. This is general information, not legal or medical advice.

Verified November 9, 2026. Imagine two jars of CBD cream. One is marketed to moisturize skin. The other promises relief from muscle pain. Both go on the skin, but that shared format does not put them in the same regulatory category. Under FDA's framework, the product's intended use—not simply the word “cream” or “cosmetic”—is central.

For CBD skin care, the practical question is what the seller promises, followed by what supports the finished product's safety. A professional-looking ingredient list cannot answer either question by itself.

The line runs through intended use, not the jar

FDA's cosmetic-versus-drug explainer identifies moisturizers among cosmetics. Products intended to diagnose, cure, mitigate, treat or prevent disease, or affect the body's structure or functions, meet the drug definition. A product can be both and must meet the applicable requirements for both categories.

FDA gives a particularly useful comparison: massage oil intended simply to lubricate skin and impart fragrance is a cosmetic; massage oil intended to relieve muscle pain is a drug. Applying that distinction to CBD means asking what the cream is intended to do, not assuming topical use makes it cosmetic-only.

These hypothetical descriptions illustrate the boundary, not approved wording:

• “Moisturizes skin” describes a cosmetic purpose. It does not establish that a particular formula is safe or properly labeled.
• “Relieves muscle pain” describes a therapeutic purpose in FDA's own example.
• “Regenerates cells” is among FDA's examples of claims that establish a drug intended use, even when used to market an appearance-related product.

This is not a wording loophole. FDA says intended use can be established through labeling, advertising, internet promotions, consumer perception and certain ingredients. A restrained jar label does not settle the issue if the accompanying website makes therapeutic promises. “Cosmeceutical” is not a separate legal category recognized by the federal food-and-drug statute.

CBD is not automatically prohibited—or automatically cleared

Question 13 of FDA's freshly reviewed cannabis and CBD FAQ says cannabis-derived ingredients are not specifically prohibited or restricted by its cosmetic ingredient regulations. The agency immediately qualifies that point: no ingredient may be used if it makes a cosmetic adulterated or misbranded.

That is not blanket approval of CBD skin care. Cosmetics and their ingredients generally do not require FDA premarket approval, except for certain color additives. They still must satisfy applicable safety and labeling requirements. A CBD product presented as a drug faces a different framework; calling it skin care does not waive drug requirements.

Nor does this FDA discussion settle controlled-substance classification, state sales restrictions or local licensing. Those are separate questions. This article does not import the future federal hemp dates discussed in our earlier coverage into a claim that any particular cream is lawful nationwide.

MoCRA puts obligations behind the cosmetic label

The Modernization of Cosmetics Regulation Act of 2022, or MoCRA, expanded FDA's cosmetic oversight. It did not turn cosmetic marketing into a product-approval system.

The responsible person is generally the manufacturer, packer or distributor whose name appears on the label. FDA identifies several important obligations:

• Safety substantiation: the responsible person must ensure and maintain records supporting adequate substantiation of the cosmetic product's safety.
• Serious adverse-event reporting: the responsible person must report serious adverse events associated with US use to FDA within 15 business days. Additional medical or other information received within one year of the initial report also has a 15-business-day submission requirement.
• Registration and listing: subject to exemptions, manufacturers and processors must register facilities and renew every two years; responsible persons must list marketed cosmetic products, including ingredients, and provide updates annually.

Certain small businesses are exempt from specified registration, listing and GMP requirements. That is not a general exemption from making safe, properly labeled cosmetics. A missing registration number on a package is not, by itself, enough to determine whether a business violates the law.

FDA also has mandatory recall authority under specified conditions involving serious health risks when the responsible person refuses a voluntary recall. “Not preapproved” does not mean “outside FDA oversight.”

Safety substantiation is more than a CBD number

FDA's small-business cosmetics fact sheet explains that it does not prescribe specific tests for every cosmetic or ingredient. Relevant existing safety data may help, but scientifically robust evidence must support the product's safety; additional testing may be needed to fill gaps.

The same guidance highlights microbiological safety and contamination, including contamination during consumer use. For a cream, therefore, a cannabinoid measurement answers a narrower question than whether the finished formulation is adequately supported as safe under its intended conditions of use.

A certificate of analysis may be useful evidence, but it is not automatically the complete safety file. Our COA reading guide explains how to identify what a report actually covers. Neither a CBD concentration nor an attractive “tested” badge establishes therapeutic effectiveness.

What the label can reveal—and what it cannot

FDA's labeling summary describes requirements including product identity, net contents, business identification and retail ingredient declarations. These help identify the product; their presence does not show that FDA approved the formula or reviewed its claims.

MoCRA also adds a useful accountability check. FDA's registration and listing guidance, Appendix B, Q3, explains that a cosmetic label must include a domestic address, domestic phone number or electronic contact information through which the responsible person can receive adverse-event reports. This reporting channel should not be confused with the separate business-identification requirement.

Finally, distinguish a regulatory submission from endorsement. FDA's current registration and listing page expressly says registration and listing are neither an approval program nor a promotional tool. FDA does not issue certificates verifying compliance with those requirements. A registration number cannot prove a cream works, is safe for an individual or is lawfully marketed for pain relief.

The useful sequence is simple: read the promised purpose, examine the evidence's scope and identify who is accountable. For the broader category distinctions, see our CBD labels explainer. Follow further reporting in the US edition.

Sources and limits

All seven linked FDA sources were freshly consulted November 9, 2026. This is general reporting, not medical or legal advice, a product endorsement or a complete compliance checklist. It evaluates no specific formulation and makes no finding about an individual seller. It does not establish the current status of every MoCRA implementing rule or replace state-specific review. Our editorial standards explain our verification approach.